Related Experiment Video
Updated: Sep 2, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Renal Denervation for Resistant Hypertension: A Concise Update on Treatment Options and the Latest Clinical Evidence
1Heart Center Leipzig at University of Leipzig, Leipzig, Germany. Karl.Fengler@medizin.uni-leipzig.de.
Abstract:
Evidence from recent sham-controlled trials supports the use of endovascular renal denervation (RDN) to lower blood pressure in general as well as in treatment-resistant hypertension. According to recent studies, the effects of RDN are long lasting. Newer technologies using multipolar radiofrequency catheters and an additional ablation of the renal side branches as well as ultrasound with improved circumferential tissue penetration have made these advances possible. This has initiated a change of the perspective on RDN in clinical guidelines and has thereby set a cornerstone for a broader clinical application of RDN in the future.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Direct Renin Inhibitors
Hypertension IV: Drug Therapy and Lifestyle Modifications
Heart Failure V: Medical Management
Heart Failure Drugs: Diuretics
Hypertension II: Pathophysiology

